AbCellera Biologics Inc.
ABCL
$3.73
$0.092.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -64.48% | 23.88% | -33.36% | 33.06% | -38.39% |
| Total Depreciation and Amortization | 2.49% | 6.89% | 136.49% | -147.26% | 0.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.87% | -29.03% | -42.20% | 384.39% | 55.11% |
| Change in Net Operating Assets | -7.95% | -260.58% | -29.78% | 360.10% | 28.70% |
| Cash from Operations | -62.31% | -180.46% | -44.43% | 72.30% | 3.62% |
| Capital Expenditure | 33.20% | -25.66% | 31.95% | 15.59% | 7.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 346.21% | -199.33% | -63.82% | 131.08% | -69.24% |
| Cash from Investing | 214.70% | -500.89% | -77.77% | 865.47% | -92.90% |
| Total Debt Issued | 37.22% | -10.46% | 4.22% | 77.20% | 17.47% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 97.95% | -4,888.76% | -0.56% | 3.80% | -0.55% |
| Cash from Financing | 318.43% | -156.53% | 44.13% | 31.70% | 18.63% |
| Foreign Exchange rate Adjustments | -171.48% | 28.98% | 127.31% | -688.56% | 953.49% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 86.12% | -2,372.32% | -90.09% | 236.97% | -187.60% |